Jonathan Pachter/LinkedIn
May 9, 2025, 08:47
Jonathan Pachter: FDA Grants Accelerated Approval for 1st Targeted Therapy in KRAS-Mutant LGSOC
Jonathan Pachter, Chief Scientific Officer at Verastem, shared a post on LinkedIn:
“I’m so excited to share the accelerated approval today of our dual RAF/MEK inhibitor avutometinib in combination with our FAK inhibitor defactinib for patients with KRAS mutant low grade serous ovarian cancer (LGSOC).
I’m proud of the team at Verastem Oncology, and I’m especially gratified that we are able to provide the first therapy specifically approved for patients with this underserved type of ovarian cancer.”
Read Full Article on FDA.Gov.
Ovarian Cancer: Symptoms, Causes, Stages, Diagnosis and Treatment
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 27, 2025, 07:35
Jul 27, 2025, 06:56
Jul 27, 2025, 06:39
Jul 27, 2025, 06:30
Jul 27, 2025, 06:13
Jul 27, 2025, 06:10
Jul 27, 2025, 06:08